Literature DB >> 1645326

Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production.

T Shimozato1, M Iwata, H Kawada, N Tamura.   

Abstract

We previously showed that human immunoglobulin preparation for intravenous use (IGIV) suppresses the in vitro production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) by rabbit peritoneal exudate cells (PEC) stimulated with lipopolysaccharide (LPS). In this study we investigated the mechanism of the suppression. IGIV treated at pH4 (pH4-G) was used as IGIV. Fc fragments of pH4-G, as well as untreated pH4-G, suppressed TNF-alpha and IL-1 production by rabbit PEC stimulated with LPS. The interaction of pH4-G with PEC also resulted in generation of cyclic adenosine 3':5'-monophosphate (cAMP), known to be an intracellular second messenger. N6, 2'-0-dibutyryl cAMP (BtcAMP), a lipid-soluble derivative of cAMP, and cholera toxin (CT), an adenylate cyclase activating agent, also suppressed the production of TNF-alpha and IL-1. Further N-[2-(methylamino) ethyl]-5-isoquinolinesulphonamide dihydrochloride (H-8), an inhibitor of cAMP-dependent protein kinases, abrogated the suppression by pH4-G of the productions. These results indicate that the binding of IGIV to PEC via Fc gamma receptors (Fc gamma R) induces the elevation of intracellular cAMP levels, resulting in the suppression of LPS-induced TNF-alpha and IL-1 productions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645326      PMCID: PMC1384367     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

Review 1.  Biological activities residing in the Fc region of immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

2.  Prostaglandins as endogenous mediators of interleukin 1 production.

Authors:  S L Kunkel; S W Chensue; S H Phan
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

3.  Regulation of interleukin 1 production by mouse peritoneal macrophages. Effects of arachidonic acid metabolites, cyclic nucleotides, and interferons.

Authors:  S R Brandwein
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

4.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

5.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

6.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate.

Authors:  P J Knudsen; C A Dinarello; T B Strom
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

7.  Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.

Authors:  Y Katakami; Y Nakao; T Koizumi; N Katakami; R Ogawa; T Fujita
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.

Authors:  H Hidaka; M Inagaki; S Kawamoto; Y Sasaki
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

9.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.

Authors:  S L Kunkel; M Spengler; M A May; R Spengler; J Larrick; D Remick
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

10.  Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes.

Authors:  P H Hart; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

View more
  12 in total

1.  Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Authors:  Kazuki Murakami; Chiaki Suzuki; Fujio Kobayashi; Atsushi Nakano; Akihiro Fujii; Kaoru Sakai; Teruaki Imada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-31       Impact factor: 3.000

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 3.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 4.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages.

Authors:  W W Zhong; P A Burke; M E Drotar; S R Chavali; R A Forse
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

6.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

7.  Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.

Authors:  A A Pall; M Varagunam; D Adu; N Smith; N T Richards; C M Taylor; J Michael
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 8.  Novel therapies for pemphigus vulgaris: an overview.

Authors:  Oliver A Perez; Timothy Patton
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP.

Authors:  D L Hoover; A M Friedlander; L C Rogers; I K Yoon; R L Warren; A S Cross
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Intravenous immunoglobulin preparation prevents the production of pro-inflammatory cytokines by modulating NFκB and MAPKs pathways in the human monocytic THP-1 cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Fujio Kobayashi; Atsushi Nakano; Akihito Kamizono
Journal:  Inflamm Res       Date:  2014-05-29       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.